1 Diplopia success
was similar between 1- and 2-muscle surgery, owing to a great
2 Graft function
was similar between ABOi (creatinine, 140.3 mumol/L) and ABOc
3 ian follow-up of 52 months (October 2016), overall survival
was similar between arms (hazard ratio, 1.218; 95% CI, 0.861
4 Median overall survival
was similar between both arms with 10.03 months on PaCE and 1
5 The T-cell response to immunization
was similar between genotypes, suggesting that the contributi
6 The morphology of microcystoid macular changes
was similar between glaucomatous and nonglaucomatous eyes.
7 In the meta-analysis, the composite endpoint
was similar between groups (hazard ratio [HR]: 0.820; p = 0.2
8 Sympathetic BRS
was similar between groups (P = 0.927), whereas cardiac BRS (
9 The recall rate
was similar between groups (RR, 0.95; 95% CI: 0.84, 1.06), wh
10 The primary end point at 12 months
was similar between groups.
11 Median LOS
was similar between IVIG and non-IVIG groups (26 [13-49] vs 2
12 The incidence of adverse events
was similar between PA101 and placebo treatments, most advers
13 The rate of adverse events
was similar between patients in the deutetrabenazine 36 mg/da
14 The risk of 3-month mortality
was similar between patients randomised to intensive BP-lower
15 The prevalence of CRC
was similar between patients with confirmed serrated polyposi
16 e study (n=40 [20%]), functional serotype-specific antibody
was similar between schedules.
17 The degree of EIAH
was similar between sexes, and regardless of sex, those who d
18 lation, the overall response rate (ORR) was 56% (29/52) and
was similar between the 10 mg/kg Q2W and 10 and 20 mg/kg QW/Q
19 Although MSI
was similar between the 2 approaches, MSI3-slices performed p
20 glutamate release, although short-term synaptic plasticity
was similar between the groups.
21 's work of breathing, the attenuation of quadriceps fatigue
was similar between the sexes.
22 70 of 1391 TWENTE trial participants (98.5% follow-up), TVF
was similar between those in the ZES (16.1%) and EES (18.1%)
23 giography-guided (6.9% vs. 8.4%, p = 0.22) although the TVR
was similar between two groups (6.0% vs. 6.0%, p = 0.97).
24 Weight gain
was similar between UPI/OIR and control/OIR pups.
25 Although the prevalence of AAA
was similar between vehicle and CAR-DCN groups, the severity
26 Fetal risk
was similar between women taking </=5 mg warfarin daily and w
27 Irs1 mRNA levels
were similar between all four groups of offspring, suggesting
28 asses and the time needed by scavengers to detect carcasses
were similar between both types of carcasses.
29 HHV-6 shedding rate and viral load
were similar between children with primary or chronic infecti
30 The rates of adverse events
were similar between erenumab and placebo.
31 Overall AE rates
were similar between evolocumab and control in the parent tri
32 Treatment-related serious adverse events
were similar between groups (13 [11%] in the ceritinib group
33 Mean mitral valve gradients
were similar between groups (6.4 +/- 2.3 mm Hg vs. 5.8 +/- 2.
34 and fluid intake, weight gain and physical activity levels
were similar between groups from days 7 to 10.
35 The absolute increase in cardiac output and CVC
were similar between groups, whereas FVC increased to a great
36 Epinephrine levels during hypoglycemia
were similar between groups.
37 For living donor recipients, the actuarial 15-year PS rates
were similar between groups.
38 The 1-year patient and graft survival rates
were similar between groups.
39 In the ILLUMENATE Pivotal Study, baseline characteristics
were similar between groups: 50% had diabetes mellitus, 41% w
40 Overall, effect direction and magnitude
were similar between isolated and nonisolated clefts, suggest
41 controls (an increase of 28.7%, P=0.041), but vGLUT2 levels
were similar between medicated schizophrenia subjects and con
42 Quality of life, blood pressure, and polysomnography
were similar between protocols.
43 ide help to B cells for developing into Ab-secreting cells,
were similar between responders and nonresponders.
44 the PCI group ($9944 versus $4440; P<0.001) but by 3 years
were similar between the 2 groups ($16 792 versus $16 737; P=
45 ted mean difference 0.24, 95% CI 0.04 to 0.44); AQLQ scores
were similar between the DVDB group and the face-to-face grou
46 Levels of HbA1c and FPG
were similar between the evolocumab and placebo groups over t
47 Plaque volumes at 1 year
were similar between the ramipril and placebo groups (162.1 +
48 Adverse events
were similar between the subgroups.
49 Adverse events were reported as expected and
were similar between the two groups.
50 e 3-4 adverse events (52 [7%] patients vs 31 [8%] patients)
were similar between the two groups.